Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Illinois at Chicago
With
National Cancer Institute (NCI)
Age
50–75
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
completed REDUCE trial (Year 4 exit biopsy with blocks and HE slides available; i.e., U.S. participants only)
compliant with assigned treatment based on either: (dutasteride group) at least 3 post-baseline serum DHT levels ≥ 50% lower than baseline, or (placebo group) at least 3 post-baseline serum DHT levels with none showing ≥ 50% decrease from baseline
You may not be if
N/A
Clareo Health | Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
